Conditions Flashcards
(44 cards)
Symptoms of scleroderma
CREST
Calcinosis: calcium deposit in skin
Raynaud’s Phenomenon: spasms of blood vessels in response to cold/stress
Esophageal dysfunction: reflux, decreased motility
Sclerodactyly: thickening/tightening of skin of fingers/hands
Telangiectasia: dilation of capillaries causing red marks on skin
Examination findings of scleroderma
Abnormal nail fold capillaries/torn nails
Palmar erythema
Digital ulcers / pitted scars
Calcinosis
Telangiectasia
Perioral skin tightening
Joint crepitus (wrist/ankle)
Pulmonary complications of scleroderma
Pulmonary HTN
Interstitial lung disease
Pleural effusion
Lung cancer
Acute onset monoarthritis workup
FBC
LFT
Calcium
U+E
Urate
RF
Anti-CCP
ANA
CRP
XR
Poor prognostic features of RA
RF positive
anti-CCP positive
>20 joints swollen at presentation
Early functional impairment
Early age of onset
Smoking
Measures of disease activity in RA
ESR/CRP
Number of tender/swollen joints
Duration of early morning stiffness
Functional assessment
Visual analogue scale for patient reported global assessment
Ix for RA
RF
anti-CCP - most sens 94%
ESR/CRP
Normal Ix does not rule out RA!!
RA XR findings
Involve Thumb IPJ and all MCPJ
MC head erosions
MCPJ osteopaenia
Joint space narrowing
Carpal erosions
Diagnostic features of RA
Fhx
Early morning stiffness > 1hr
Swelling in >=5 joints
Symmetrical
RF/ anti-CCP positive
sx > 6/12
Raised ESR/CRP
Bony erosions on XR
RA mx
Simple analgesics
Omega-3 supplements
DMARDS
Steroids
Weight loss
Exercise
Psychosocial support
Sleep promotion
Vaccination
Maintaining remission of RA
Methotrexate 10mg weekly PLUS folic acid 5mg weekly (separate day)
PO pred 5-15mg and slow taper
MTX patient education
EtOH 2std max 2x per week
Contraception
Drug interactions w/ folate antagonists e.g. trimethoprim
Vaccination; pneumococcal, influenza
Avoid live vaccines
Regular LFT/renal monitoring
Weekly folic acid
Sun protection
MTX ADRs
Stomatitis
Alopecia
N/v
diarrhoea
myelosuppression
hepatotoxicity
Infections
MTX monitoring
4 weekly
- Efficacy, ADR
- Bloods; FBC/LFT/albumin/Cr for 3/12 or after increasing dose -> then 8 weeks for 6 months -> then 12 weekly
Long term health monitoring RA
- Joint effects – number, tenderness, function
- Extra-articular involvement; nodules, rash
- CVD: BP, renal function
- Risk of infection on immunomodulators
- Toxicity; monitor for toxicity (skin, lungs, GIT, heart)
- Lifestyle – smoking, BMI
- ADLS; function, sleep, mood, fatigue
- Annual foot review
- Medication adherence
- Steroids – osteoporosis risk, BP, lipids, cataracts
Osteoporosis risk factors
Female
Low body weight
Caucasian/Asian
Prev minimal trauma #
Hx of falls
Fhx
Premature menopause
RA
Hyperthyroidism
Malabsorption disease - coeliac
Smoking/ETOH
Physical inactivity
Lack of sunlight
Long term steroid use
PPI
SSRI
Major osteoporosis risk factors for MBS BMD
Parental hx #
Premature menopause
Low body weight
Immobility
Smoking
Alcohol > 2 std per day
RA
Hyperthyroid/hyperparathyroid
CKD
Coealic
DM
Depression
Steroids > 3/12 >=7.5mg / day
SSRI/PPIs
Minimal trauma # flow chart for postmenopausal women and men >50yo
Hip/vertebral -> straight to antiresorptives (can do baseline BMD but not essential)
Any other site -> BMD
-> if T score <=-1.5 -> antiresorptive
-> if T score > -1.5 -> specialist review
BMD screening flow chart
Age >=70yo or Major risk factors do BMD
if T score <= -2.5 -> antiresorptives
if T score >-2.5 -> Garvan fracture risk
Garvan # risk;
- Hip fracture >3%, any fracture >20% then tx antiresorptives
- if low risk - implement lifestyle changes
After tx - screen 2 yearly
Osteoporosis lifestyle mx
Falls prevention; home hazard removal, good footwear
Exercise; weight-bearing and balance training
Diet
- Calcium 1300mg / day
Sun exposure
Reduce alcohol/smoking
Weight loss
Bisphosphonate therapy for osteoporosis
Prior to prescribing
- Baseline renal, Ca, vitamin D (ensure replete >50)
Alendronate 70mg PO weekly
- Empty stomach, 2hrs from Ca/Iron/antacids
- Remain upright 60min
IV Zolendronic acid IV to avoid GIT ADR
ADR
- Myalgia, hypocalcaemia, AKI, osteonecrosis of jaw, oesophagitis
Duration
- 5 years oral, 3 years IV, if high risk (10 years oral, 6 years IV)
- After stop - BMD 2 years later
RANKL inhibitor for osteoporosis
Denosumab 60mg subcut every 6/12
- Ensure vitamin D replete and sufficient Ca intake
- Can be used in CKD IV
- Crucial compliance - high risk fracture if late
- Duration; indefinite or replace with bisphosphonates
- Avoids GIT ADR
SERM for osteoporosis
Raloxifene 60mg daily
<60 yo and menopausal
Best if spinal osteoporosis
Reduces risk of breast Ca - but increase VTE/CVA
Tibolone for osteoporosis
Tibolone 2.5mg daily
<60yo, menopausal sx
Increase risk breast Ca/CVA